Mendus AB (publ) (IMMU.ST)
SEK 4.87
(-3.66%)
SEK 4.87
(-3.66%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 51.22 Million SEK | -51.65% |
| 2022 | 105.94 Million SEK | 64.92% |
| 2021 | 64.24 Million SEK | -4.92% |
| 2020 | 67.56 Million SEK | 117.62% |
| 2019 | 31.04 Million SEK | -29.96% |
| 2018 | 44.33 Million SEK | -21.66% |
| 2017 | 56.58 Million SEK | 194.98% |
| 2016 | 19.18 Million SEK | 27.39% |
| 2015 | 15.05 Million SEK | 135.04% |
| 2014 | 6.4 Million SEK | -31.06% |
| 2013 | 9.29 Million SEK | 344.35% |
| 2012 | 2.09 Million SEK | 26.97% |
| 2011 | 1.64 Million SEK | -29.2% |
| 2010 | 2.32 Million SEK | 113.0% |
| 2009 | 1.09 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 42.8 Million SEK | -16.44% |
| 2024 Q2 | 42.58 Million SEK | -0.52% |
| 2023 Q3 | 56.58 Million SEK | -50.97% |
| 2023 FY | 51.22 Million SEK | -51.65% |
| 2023 Q1 | 128 Million SEK | 20.82% |
| 2023 Q4 | 51.22 Million SEK | -9.47% |
| 2023 Q2 | 115.4 Million SEK | -9.84% |
| 2022 Q2 | 85.01 Million SEK | -5.13% |
| 2022 Q3 | 91.06 Million SEK | 7.12% |
| 2022 Q4 | 105.94 Million SEK | 16.34% |
| 2022 FY | 105.94 Million SEK | 64.92% |
| 2022 Q1 | 89.62 Million SEK | 39.5% |
| 2021 Q4 | 64.24 Million SEK | 15.39% |
| 2021 Q1 | 62.88 Million SEK | -6.93% |
| 2021 FY | 64.24 Million SEK | -4.92% |
| 2021 Q2 | 56.43 Million SEK | -10.26% |
| 2021 Q3 | 55.67 Million SEK | -1.35% |
| 2020 Q2 | 27.48 Million SEK | -1.31% |
| 2020 Q1 | 27.84 Million SEK | -10.3% |
| 2020 FY | 67.56 Million SEK | 117.62% |
| 2020 Q3 | 11.79 Million SEK | -57.09% |
| 2020 Q4 | 67.56 Million SEK | 472.94% |
| 2019 Q4 | 31.04 Million SEK | 28.93% |
| 2019 FY | 31.04 Million SEK | -29.96% |
| 2019 Q2 | 26.11 Million SEK | 20.63% |
| 2019 Q3 | 24.08 Million SEK | -7.78% |
| 2019 Q1 | 21.64 Million SEK | -51.17% |
| 2018 Q3 | 20.45 Million SEK | 30.86% |
| 2018 Q2 | 15.63 Million SEK | 0.37% |
| 2018 Q1 | 15.57 Million SEK | -72.48% |
| 2018 FY | 44.33 Million SEK | -21.66% |
| 2018 Q4 | 44.33 Million SEK | 116.73% |
| 2017 Q4 | 56.58 Million SEK | 201.86% |
| 2017 Q3 | 18.74 Million SEK | 16.57% |
| 2017 Q2 | 16.08 Million SEK | -20.61% |
| 2017 Q1 | 20.25 Million SEK | 5.6% |
| 2017 FY | 56.58 Million SEK | 194.98% |
| 2016 Q1 | 9.79 Million SEK | 1.9% |
| 2016 Q3 | 8.46 Million SEK | -43.8% |
| 2016 Q4 | 19.18 Million SEK | 126.65% |
| 2016 Q2 | 15.05 Million SEK | 53.78% |
| 2016 FY | 19.18 Million SEK | 27.39% |
| 2015 FY | 15.05 Million SEK | 135.04% |
| 2015 Q4 | 9.61 Million SEK | 40.23% |
| 2015 Q1 | 6.07 Million SEK | -10.12% |
| 2015 Q3 | 6.85 Million SEK | 6.97% |
| 2015 Q2 | 6.4 Million SEK | 5.54% |
| 2014 Q4 | 6.75 Million SEK | 20.53% |
| 2014 FY | 6.4 Million SEK | -31.06% |
| 2014 Q3 | 5.6 Million SEK | -39.7% |
| 2014 Q2 | 9.29 Million SEK | 104.41% |
| 2014 Q1 | 4.54 Million SEK | 96.69% |
| 2013 Q3 | - SEK | -100.0% |
| 2013 Q4 | 2.31 Million SEK | 0.0% |
| 2013 Q2 | 2.09 Million SEK | 0.0% |
| 2013 FY | 9.29 Million SEK | 344.35% |
| 2012 Q3 | 1.34 Million SEK | -18.28% |
| 2012 FY | 2.09 Million SEK | 26.97% |
| 2012 Q4 | 1.34 Million SEK | 0.0% |
| 2012 Q1 | 1.64 Million SEK | 0.0% |
| 2012 Q2 | 1.64 Million SEK | 0.0% |
| 2011 FY | 1.64 Million SEK | -29.2% |
| 2010 FY | 2.32 Million SEK | 113.0% |
| 2009 FY | 1.09 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AcouSort AB (publ) | 10.37 Million SEK | -393.592% |
| Alzinova AB (publ) | 9.33 Million SEK | -448.977% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -1057.366% |
| BioArctic AB (publ) | 139.5 Million SEK | 63.28% |
| Camurus AB (publ) | 414.81 Million SEK | 87.651% |
| Kancera AB (publ) | 17.97 Million SEK | -184.932% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -342.778% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -25.37% |
| Xintela AB (publ) | 14.01 Million SEK | -265.501% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -2071.471% |
| Active Biotech AB (publ) | 13.4 Million SEK | -282.276% |
| Amniotics AB (publ) | 10.54 Million SEK | -385.683% |
| Cantargia AB (publ) | 54.97 Million SEK | 6.813% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -1234.68% |
| CombiGene AB (publ) | 4.15 Million SEK | -1132.556% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 27.972% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -271.962% |
| Genovis AB (publ.) | 98.04 Million SEK | 47.755% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -176.982% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -167.298% |
| Saniona AB (publ) | 86.08 Million SEK | 40.493% |
| OncoZenge AB (publ) | 1.69 Million SEK | -2915.009% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 51.944% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 96.728% |
| Intervacc AB (publ) | 21.68 Million SEK | -136.278% |
| LIDDS AB (publ) | 3.75 Million SEK | -1263.818% |
| Lipum AB (publ) | 7.53 Million SEK | -579.557% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -893.117% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 58.683% |
| NextCell Pharma AB | 13.68 Million SEK | -274.204% |
| Simris Alg AB (publ) | 148.93 Million SEK | 65.606% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -339.021% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -886.055% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 89.376% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 28.706% |
| Ziccum AB (publ) | 6.38 Million SEK | -701.894% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -48.036% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -91.796% |
| Corline Biomedical AB | 6.78 Million SEK | -654.529% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 16.513% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -217.832% |
| Aptahem AB (publ) | 8.99 Million SEK | -469.304% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -10.925% |
| Fluicell AB (publ) | 8.91 Million SEK | -474.593% |
| Biovica International AB (publ) | 34.76 Million SEK | -47.338% |
| Abliva AB (publ) | 16.78 Million SEK | -205.256% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 76.13% |
| 2cureX AB (publ) | 2.93 Million SEK | -1645.315% |
| I-Tech AB | 16.2 Million SEK | -216.106% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 95.681% |
| Cyxone AB (publ) | 4.69 Million SEK | -991.287% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -284.341% |
| Biosergen AB | 5.08 Million SEK | -907.375% |
| Nanologica AB (publ) | 79.32 Million SEK | 35.426% |
| SynAct Pharma AB | 51.83 Million SEK | 1.175% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -544.421% |
| BioInvent International AB (publ) | 90.45 Million SEK | 43.368% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 71.792% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -2755.351% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -301.954% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -605.579% |